13 results on '"Güngör, Deniz"'
Search Results
2. Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey
- Author
-
Brands, Marion M. G., Güngör, Deniz, van den Hout, Johanna M. P., Karstens, Francois P. J., Oussoren, Esmee, Plug, Iris, Boelens, Jaap Jan, van Hasselt, Peter M., Hollak, Carla E. M., Mulder, Margot F., Gozalbo, Estela Rubio, Smeitink, Jan A., Smit, G. Peter A., Wijburg, Frits A., Meutgeert, Hanka, and van der Ploeg, Ans T.
- Published
- 2015
- Full Text
- View/download PDF
3. How to describe the clinical spectrum in Pompe disease?
- Author
-
Güngör, Deniz and Reuser, Arnold J.J.
- Published
- 2013
- Full Text
- View/download PDF
4. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy
- Author
-
Reuser Arnold JJ, Hop Wim CJ, de Vries Juna M, Güngör Deniz, van Doorn Pieter A, van der Ploeg Ans T, and Hagemans Marloes LC
- Subjects
Pompe disease ,survival ,acid maltase deficiency ,lysosomal storage disease ,glycogen storage disease type II ,prognostic factors ,natural course ,patient reported outcome measures ,Medicine - Abstract
Abstract Background Pompe disease is a rare lysosomal storage disorder characterized by muscle weakness and wasting. The majority of adult patients have slowly progressive disease, which gradually impairs mobility and respiratory function and may lead to wheelchair and ventilator dependency. It is as yet unknown to what extent the disease reduces the life span of these patients. Our objective was to determine the survival of adults with Pompe disease not receiving ERT and to identify prognostic factors associated with survival. Methods Data of 268 patients were collected in a prospective international observational study conducted between 2002 and 2009. Survival analyses from time of diagnosis and from time of study entry were performed using Kaplan-Meier curves and Cox-proportional-hazards regression. Results Median age at study entry was 48 years (range 19-79 years). Median survival after diagnosis was 27 years, while median age at diagnosis was 38 years. During follow-up, twenty-three patients died prior to ERT, with a median age at death of 55 (range 23-77 years). Use of wheelchair and/or respiratory support and patients' score on the Rotterdam Handicap Scale (RHS) were identified as prognostic factors for survival. Five-year survival for patients without a wheelchair or respiratory support was 95% compared to 74% in patients who were wheelchair-bound and used respiratory support. In a Dutch subgroup of 99 patients, we compared the observed number of deaths to the expected number of deaths in the age- and sex-matched general population. During a median follow-up of 2.3 years, the number of deaths among the Dutch Pompe patients was higher than the expected number of deaths in the general population. Conclusion Our study shows for the first time that untreated adults with Pompe disease have a higher mortality than the general population and that their levels of disability and handicap/participation are the most important factors associated with mortality. These results may be of relevance when addressing the effect of ERT or other potential treatment options on survival.
- Published
- 2011
- Full Text
- View/download PDF
5. Survival and Prognostic Factors Prior to Enzyme Replacement Therapy in 302 Children and Adults with Pompe Disease
- Author
-
Güngör, Deniz, de Vries, Juna M., Hop, Wim C.J., Reuser, Arnold J.J., van Doorn, Pieter A., van der Ploeg, Ans T., and Hagemans, Marloes L.C.
- Published
- 2011
- Full Text
- View/download PDF
6. A conceptual disease model for adult Pompe disease.
- Author
-
Kanters, Tim A., Redekop, W. Ken, Rutten-Van Mölken, Maureen P. M. H., Kruijshaar, Michelle E., Güngör, Deniz, van der Ploeg, Ans T., and Hakkaart, Leona
- Subjects
GLYCOGEN storage disease type II ,RANDOMIZED controlled trials ,QUALITY of life ,REGRESSION analysis ,DECISION making ,MUSCLE strength - Abstract
Background: Studies in orphan diseases are, by nature, confronted with small patient populations, meaning that randomized controlled trials will have limited statistical power. In order to estimate the effectiveness of treatments in orphan diseases and extrapolate effects into the future, alternative models might be needed. The purpose of this study is to develop a conceptual disease model for Pompe disease in adults (an orphan disease). This conceptual model describes the associations between the most important levels of health concepts for Pompe disease in adults, from biological parameters via physiological parameters, symptoms and functional indicators to health perceptions and final health outcomes as measured in terms of health-related quality of life. Methods: The structure of the Wilson-Cleary health outcomes model was used as a blueprint, and filled with clinically relevant aspects for Pompe disease based on literature and expert opinion. Multiple observations per patient from a Dutch cohort study in untreated patients were used to quantify the relationships between the different levels of health concepts in the model by means of regression analyses. Results: Enzyme activity, muscle strength, respiratory function, fatigue, level of handicap, general health perceptions, mental and physical component scales and utility described the different levels of health concepts in the Wilson-Cleary model for Pompe disease. Regression analyses showed that functional status was affected by fatigue, muscle strength and respiratory function. Health perceptions were affected by handicap. In turn, self-reported quality of life was affected by health perceptions. Conclusions: We conceptualized a disease model that incorporated the mechanisms believed to be responsible for impaired quality of life in Pompe disease. The model provides a comprehensive overview of various aspects of Pompe disease in adults, which can be useful for both clinicians and policymakers to support their multi-faceted decision making. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Enzyme replacement therapy and fatigue in adults with Pompe disease.
- Author
-
Güngör, Deniz, de Vries, Juna M., Brusse, Esther, Kruijshaar, Michelle E., Hop, Wim C.J., Murawska, Magda, van den Berg, Linda E.M., Reuser, Arnold J.J., van Doorn, Pieter A., Hagemans, Marloes L.C., Plug, Iris, and van der Ploeg, Ans T.
- Subjects
- *
THERAPEUTIC use of enzymes , *FATIGUE (Physiology) , *GLYCOGEN storage disease type II , *MUSCLE diseases , *GENETIC disorders , *ANALYSIS of variance , *MUSCLE strength testing , *PATIENTS - Abstract
Abstract: Background: Pompe disease is a hereditary metabolic myopathy, for which enzyme replacement therapy (ERT) has been available since 2006. We investigated whether ERT reduces fatigue in adult patients with Pompe disease. Methods: In this prospective international observational survey, we used the Fatigue Severity Scale (FSS) to measure fatigue. Repeated measures ANOVA was used to analyze the data over time. In a subgroup of patients, we also evaluated muscle strength using the Medical Research Council Scale, measured pulmonary function as Forced Vital Capacity, and assessed depression using the Hospital Anxiety and Depression Scale. Results: We followed 163 patients for a median period of 4years before ERT and for 3years during ERT. Before ERT, the mean FSS score remained stable at around 5.3 score points; during ERT, scores improved significantly by 0.13 score points per year (p<0.001). Fatigue decreased mainly in women, in older patients and in those with shorter disease duration. Patients' improvements in fatigue were moderately correlated with the effect of ERT on depression (r 0.55; CI 95% 0.07 to 0.70) but not with the effect of ERT on muscle strength or pulmonary function. Conclusions: Fatigue is a common and disabling problem in patients with early and advanced stages of Pompe disease. Our finding that ERT helps to reduce fatigue is therefore important for this patient population, irrespective of the mechanisms underlying this effect. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
8. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study.
- Author
-
Güngör, Deniz, Kruijshaar, Michelle E., Plug, Iris, D'Agostino Sr., Ralph B., Hagemans, Marloes L. C., van Doorn, Pieter A., Reuser, Arnold J. J., and van der Ploeg, Ans T.
- Subjects
- *
THERAPEUTIC use of enzymes , *GLYCOGEN storage disease type II , *DRUG efficacy , *MUSCLE disease treatment , *MUSCLE strength , *PULMONARY function tests , *THERAPEUTICS - Abstract
Background: Pompe disease is a rare metabolic myopathy for which disease-specific enzyme replacement therapy (ERT) has been available since 2006. ERT has shown efficacy concerning muscle strength and pulmonary function in adult patients. However, no data on the effect of ERT on the survival of adult patients are currently available. The aim of this study was to assess the effect of ERT on survival in adult patients with Pompe disease. Methods: Data were collected as part of an international observational study conducted between 2002 and 2011, in which patients were followed on an annual basis. Time-dependent Cox's proportional hazards models were used for univariable and multivariable analyses. Results: Overall, 283 adult patients with a median age of 48 years (range, 19 to 81 years) were included in the study. Seventy-two percent of patients started ERT at some time during follow-up, and 28% never received ERT. During follow-up (median, 6 years; range, 0.04 to 9 years), 46 patients died, 28 (61%) of whom had never received ERT. After adjustment for age, sex, country of residence, and disease severity (based on wheelchair and ventilator use), ERT was positively associated with survival (hazard ratio, 0.41; 95% CI, 0.19 to 0.87). Conclusion: This prospective study was the first to demonstrate the positive effect of ERT on survival in adults with Pompe disease. Given the relatively recent registration of ERT for Pompe disease, these findings further support its beneficial impact in adult patients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy.
- Author
-
Güngör, Deniz, de Vries, Juna M, Hop, Wim C J, Reuser, Arnold J J, van Doorn, Pieter A, van der Ploeg, Ans T, and Hagemans, Marloes L C
- Subjects
- *
MORTALITY , *GLYCOGEN storage disease type II , *ENZYMES , *PEOPLE with disabilities , *ADULTS - Abstract
Background: Pompe disease is a rare lysosomal storage disorder characterized by muscle weakness and wasting. The majority of adult patients have slowly progressive disease, which gradually impairs mobility and respiratory function and may lead to wheelchair and ventilator dependency. It is as yet unknown to what extent the disease reduces the life span of these patients. Our objective was to determine the survival of adults with Pompe disease not receiving ERT and to identify prognostic factors associated with survival.Methods: Data of 268 patients were collected in a prospective international observational study conducted between 2002 and 2009. Survival analyses from time of diagnosis and from time of study entry were performed using Kaplan-Meier curves and Cox-proportional-hazards regression.Results: Median age at study entry was 48 years (range 19-79 years). Median survival after diagnosis was 27 years, while median age at diagnosis was 38 years. During follow-up, twenty-three patients died prior to ERT, with a median age at death of 55 (range 23-77 years). Use of wheelchair and/or respiratory support and patients' score on the Rotterdam Handicap Scale (RHS) were identified as prognostic factors for survival. Five-year survival for patients without a wheelchair or respiratory support was 95% compared to 74% in patients who were wheelchair-bound and used respiratory support. In a Dutch subgroup of 99 patients, we compared the observed number of deaths to the expected number of deaths in the age- and sex-matched general population. During a median follow-up of 2.3 years, the number of deaths among the Dutch Pompe patients was higher than the expected number of deaths in the general population.Conclusion: Our study shows for the first time that untreated adults with Pompe disease have a higher mortality than the general population and that their levels of disability and handicap/participation are the most important factors associated with mortality. These results may be of relevance when addressing the effect of ERT or other potential treatment options on survival. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
10. Prevalence of vitamin D deficiency in Samarkand, Uzbekistan.
- Author
-
Güngör, Deniz, Biçer, Ilke, Pereira, Rob Rodrigues, Rasulov, Alisher S., Rachimov, Azamat U., Mavlyanov, Shafkat, Ponjee, Gabrielle A. E., and Brabin, Bernard J.
- Subjects
- *
VITAMIN D deficiency , *VITAMIN deficiency , *RICKETS , *CALCIUM metabolism disorders , *BONE diseases in children , *PREVENTIVE medicine , *MEDICAL care - Abstract
Background. Clinical rickets is a childhood bone disorder that is infrequently seen in the Western World. It is still frequently seen in Uzbekistan, Eastern Europe. This is the first study undertaken to estimate the prevalence and factors associated with deficiency of vitamin D in infants in this region of Eastern Europe. Methods. Information was obtained by parental questionnaires for 474 infants aged 5-61 weeks attending rural out-patient clinics in Samarkand. Blood was assayed for 25-OHD and ferritin concentration. Results. Prevalence of vitamin D deficiency (25-OHD ,30 nmol l-1) was 78.7% and was significantly associated with continued breastfeeding (p,0.05), lack of vitamin supplementation (p,0.05), residence in a rural area (p,0.05) and reduced time spent outdoors (p,0.05). Maternal characteristics did not differ between mothers of infants with and without biochemical rickets. Possible causes are a combination of factors including vitamin D deficiency in pregnancy, prolonged breastfeeding without supplementation, a vitamin D poor diet and traditional avoidance of sunlight in the first year of life. Over 40% of the children had low ferritin values. Most children with low ferritin values were also vitamin D deficient (90.3%). Almost 10% of infants had persistently low 25-OHD levels following 6 weeks of therapy (4000 IU/day). Conclusion. There is an urgent need for adherence to clear recommendations for primary and secondary prevention of this major clinical and public health problem in Samarkand infants. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
11. The Pompe survey: a summary of 10 years follow-up through patient reported outcomes on non-classic Pompe patients.
- Author
-
van der Meijden, J.C. (Chris), Güngör, Deniz, Kruijshaar, Michelle E., and van der Ploeg, Ans T.
- Published
- 2014
- Full Text
- View/download PDF
12. Impact of enzyme replacement therapy on survival in adults with Pompe disease.
- Author
-
Güngör, Deniz, Kruijshaar, Michelle, Plug, Iris, D'Agostino Sr., Ralph, Hagemans, Marloes, Reuser, Arnold, and van der Ploeg, Ans
- Subjects
- *
GLYCOGEN storage disease type II , *THERAPEUTIC use of enzymes - Abstract
An abstract of the article "Impact of enzyme replacement therapy on survival in adults with Pompe disease" by Michelle Kruijshaar, Iris Plug, Ralph D'Agostino Sr., Marloes Hagemans, Arnold Reuser, Ans van der Ploeg and Deniz Güngör is presented.
- Published
- 2013
- Full Text
- View/download PDF
13. Severely impaired health status at diagnosis of Pompe disease: A cross-sectional analysis to explore the potential utility of neonatal screening
- Author
-
Rigter, Tessel, Weinreich, Stephanie S., van El, Carla G., de Vries, Juna M., van Gelder, Carin M., Güngör, Deniz, Reuser, Arnold J.J., Hagemans, Marloes L.C., Cornel, Martina C., and van der Ploeg, Ans T.
- Subjects
- *
GLYCOGEN storage disease type II , *CROSS-sectional method , *HEART function tests , *APPLIED kinesiology , *EVOKED response audiometry , *ALPHA-glucosidases , *MEDICAL screening , *NEWBORN screening - Abstract
Abstract: Since the introduction of enzyme replacement therapy for Pompe disease, awareness and early diagnosis have gained importance. Because the therapy is most effective when started early and methods for dried bloodspot screening for Pompe disease are currently being explored, neonatal screening is getting increased attention. The objective of this study was to investigate the gains that might be achieved with earlier diagnosis by neonatal screening. For this purpose we analyzed the health and functional status of non-screened patients with Pompe disease at the time of diagnosis. Previously collected clinical data and results of an international patient-reported questionnaire were used. Cross-sectional data of 53 patients with Pompe disease diagnosed between 1999 and 2009 (aged 0–64years) were analyzed. According to the World Health Organization''s International Classification of Functioning, Disability and Health the following domains are described: body function, activity, participation and contextual factors. In all patients with classic infantile Pompe disease cardiac function, hearing, muscle strength and motor development were considerably impaired at the time of clinical diagnosis. The use of oxygen and/or nasogastric tube-feeding was reported in more than 70% of these cases. Most children, adolescents and adults had advanced muscle weakness and impaired respiratory function at the time of their diagnosis, causing varying degrees of handicap. About 12% of them used a walking device and/or respiratory support at the time of diagnosis. The severely impaired health status reported here provides a strong argument for earlier diagnosis and to further explore the potential of neonatal screening for Pompe disease. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.